Patents by Inventor Matthew D. Hellmann

Matthew D. Hellmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Determinants of cancer response to immunotherapy by pd-1 blockade
    Patent number: 12485162
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: December 2, 2025
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Timothy A. Chan, Naiyer A. Rizvi, Matthew D. Hellmann
  • MODELS FOR PREDICTING MUTANT P53 FITNESS AND THEIR IMPLICATIONS IN CANCER THERAPY
    Publication number: 20250322927
    Abstract: The present technology relates to methods, computing devices, and systems for predicting the fitness of mutant p53 based on the loss of transcription factor function and immunogenicity of a particular TP53 mutation. The fitness of mutant p53 may be used to determine whether a patient will benefit from a particular anti-cancer therapy such as immune checkpoint inhibitor therapy, adoptive T-cell therapy, or prophylactic cancer vaccine therapy.
    Type: Application
    Filed: February 16, 2022
    Publication date: October 16, 2025
    Inventors: Benjamin GREENBAUM, David HOYOS, Taha MERGHOUB, Jedd WOLCHOK, Roberta ZAPPASODI, Matthew D. HELLMANN, Zachary SETHNA, Isabell SCHULZE, Vinod BALACHANDRAN, Arnold LEVINE, Marta LUKSZA
  • DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADE
    Publication number: 20210308241
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Application
    Filed: March 15, 2021
    Publication date: October 7, 2021
    Inventors: Timothy A. Chan, Naiyer A. Rizvi, Matthew D. Hellmann
  • Determinants of cancer response to immunotherapy by PD-1 blockade
    Patent number: 10993998
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: May 4, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Timothy A. Chan, Naiyer A. Rizvi, Matthew D. Hellmann
  • DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADE
    Publication number: 20200040049
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Application
    Filed: February 22, 2019
    Publication date: February 6, 2020
    Inventors: Timothy A. Chan, Naiyer A. Rizvi, Matthew D. Hellmann
  • DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADE
    Publication number: 20180291074
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Application
    Filed: November 23, 2015
    Publication date: October 11, 2018
    Inventors: Timothy A. Chan, Naiyer A. Rizvi, Matthew D. Hellmann